CHRAC1 Polyclonal Antibody

Lane 1: Hela cell lysates; Lane 2: CHRAC1 knockout (KO) HeLa cell lysates probed with CHRAC1 Polyclonal Antibody, Unconjugated (bs-55044R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bs-55044R
Product Name	CHRAC1 Polyclonal Antibody
Applications	WB, IHC
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant fusion protein containing a sequence corresponding to amino acids 1-131 of human CHRAC1 (NP_059140.1).
Clonality	Polyclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20C for 12 months.
Target
Gene ID	54108
Swiss Prot	Q9NRG0
Subcellular location	Nucleus
Synonyms	CHRAC1;CHARC1;CHARC15;CHRAC-1;CHRAC-15;CHRAC15;YCL1
Background	DNA replication is initiated by the binding of initiation factors to the origin of replication. Nucleosomes inhibit access to the replication machinery at these origin sequences. Nucleosome remodeling factors increase the accessibility of nucleosomal DNA to transcriptional regulators (1). CHRAC15 and CHRAC17 are subunits of the nucleosomal remodeling factor CHRAC (chromatin accessibility complex),which increases the accessibility of nucleosomal DNA in an ATP-dependent manner (2). Unlike other known chromatin remodelling factors, CHRAC also functions during chromatin assembly by using ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing (3). This conversion process occurs when CHRAC organizes randomly deposited histones into a regularly spaced array (4). In the presence of CHRAC, the nucleosomal ATPase ISWI catalyses several ATP-dependent transitions of chromatin structure (5).
Application Dilution
WB	1:300-5000
IHC